1. Characterization of HCV Resistance from a 3-Day Monotherapy Study of Voxilaprevir, a Novel Pangenotypic NS3/4A Protease Inhibitor. Issue 4 (May 2018) Authors: Lawitz, Eric; Yang, Jenny C; Stamm, Luisa M; Taylor, James G; Cheng, Guofeng; Brainard, Diana M; Miller, Michael D; Mo, Hongmei; Dvory-Sobol, Hadas Journal: Antiviral therapy Issue: Volume 23:Issue 4(2018) Page Start: 325 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. In vitro Selection of Resistance to Sofosbuvir in HCV Replicons of Genotype-1 to -6. Issue 7 (October 2017) Authors: Xu, Simin; Doehle, Brian; Rajyaguru, Sonal; Han, Bin; Barauskas, Ona; Feng, Joy; Perry, Jason; Dvory-Sobol, Hadas; Svarovskaia, Evguenia S; Miller, Michael D; Mo, Hongmei Journal: Antiviral therapy Issue: Volume 22:Issue 7(2017) Page Start: 587 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Infrequent Development of Drug Resistance in HIV-1-Infected Treatment-Naive Subjects after 96 Weeks of Treatment with Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide or Elvitegravir/Cobicistat/ Emtricitabine/Tenofovir Disoproxil Fumarate. Issue 5 (July 2017) Authors: Margot, Nicolas; Cox, Stephanie; Das, Moupali; McCallister, Scott; Miller, Michael D; Callebaut, Christian Journal: Antiviral therapy Issue: Volume 22:Issue 5(2017) Page Start: 443 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Long-Term Persistence of HCV NS5A Resistance-Associated Substitutions after Treatment with the HCV NS5A Inhibitor, Ledipasvir, without Sofosbuvir. Issue 3 (April 2018) Authors: Wyles, David; Mangia, Alessandra; Cheng, Wendy; Shafran, Stephen; Schwabe, Christian; Ouyang, Wen; Hedskog, Charlotte; McNally, John; Brainard, Diana M; Doehle, Brian P; Svarovskaia, Evguenia; Miller, Michael D; Mo, Hongmei; Dvory-Sobol, Hadas Journal: Antiviral therapy Issue: Volume 23:Issue 3(2018) Page Start: 229 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Viral Blips were Infrequent in Treatment-Naive Adults Treated with Rilpivirine/Emtricitabine/Tenofovir DF or Efavirenz/Emtricitabine/Tenofovir DF through 96 Weeks. Issue 6 (August 2017) Authors: Porter, Danielle P; Kulkarni, Rima; Garner, Will; Miller, Michael D; White, Kirsten L Journal: Antiviral therapy Issue: Volume 22:Issue 6(2017) Page Start: 495 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Week 144 Resistance Analysis of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF versus Efavirenz/Emtricitabine/Tenofovir DF in Antiretroviral-Naive Patients. Issue 3 (April 2015) Authors: White, Kirsten L; Kulkarni, Rima; McColl, Damian J; Rhee, Martin S; Szwarcberg, Javier; Cheng, Andrew K; Miller, Michael D Journal: Antiviral therapy Issue: Volume 20:Issue 3(2015) Page Start: 317 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗